Michael Camilleri, MD
Dermatology · Rochester, MNNPI 1760405898
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,005 of the $5,005 with a category attached, or 100.0%. 3 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 59.9% of the total. Among dermatology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3 payments — averaging $1668.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Ironwood Pharmaceuticals, Inc$400
Across 4 payments — averaging $73,077 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vanda Pharmaceuticals Inc.$292K
What the payments were for
- Consulting fees$5,005100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 1 | $3,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,605 |
| Ironwood Pharmaceuticals, Inc | 1 | $400 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Motegrity$1,605
How this compares
$5,005 in reported general payments places this provider in the 90th percentile of 273 dermatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 13 | $922 |
| Dapsone | 24 | $850 |
| Doxycycline Hyclate | 17 | $698 |
| Prednisone | 26 | $210 |
| Triamcinolone Acetonide | 11 | $199 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Rochester
- Afsaneh AlaviRochester$71K
- Saranya WylesRochester$25K
- Nessa Aghazadeh MohandesiRochester$11K
- Alina BridgesRochester$11K
- Megha TollefsonRochester$8K
- Julia LehmanRochester$8K
- Michael WangRochester$7K
- Jennifer MartinRochester$3K
- Julio Sartori-ValinottiRochester$3K
- Ahmed AnsariRochester$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.